Efficient in vivo targeting of malignant melanoma by single-chain Fv antibody fragments

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Single-chain antibody fragments (scFvs) offer potential advantages over larger antibody formats for medical imaging.
• Melanoma radioimaging requires agents with optimal pharmacokinetics and biodistribution for effective tumor targeting.

Purpose of the Study:

• To evaluate the in vivo performance of a novel anti-melanoma scFv (B4 scFv) for radioimaging.
• To compare the biodistribution and targeting efficiency of B4 scFv with a specific monoclonal antibody (MAb LHM2) in a human melanoma xenograft model.

Main Methods:

• A mouse xenograft model of human melanoma was utilized.
• Pharmacokinetic parameters (circulation half-lives) and biodistribution of B4 scFv and MAb LHM2 were assessed.
• Tumor-to-normal tissue ratios and immunoscintigraphy were used to determine targeting efficiency.

Main Results:

• B4 scFv exhibited rapid initial clearance (t(1/2)alpha = 7 min) but a prolonged terminal half-life (t(1/2)beta = 437 min).
• Specific tumor accumulation of B4 scFv was observed, with higher kidney accumulation but lower non-specific uptake in other organs compared to MAb LHM2.
• B4 scFv demonstrated superior overall tumor targeting efficiency compared to the whole antibody.

Conclusions:

• The anti-melanoma B4 scFv shows promising results for in vivo radioimaging applications.
• scFvs represent a viable alternative to MAbs for targeted cancer imaging, offering improved tumor targeting.
• This study is the first to demonstrate the in vivo utility of an anti-melanoma scFv.